Citadel Advisors
CATX icon

Citadel Advisors’s Perspective Therapeutics CATX Stock Holding History

Citadel Advisors’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,700
Closed -$44.6K – 13768
2026
Q1 		$44.6K Buy
+10,700
New +$45.2K ﹤0.01% 12442
2025
Q2 		– Sell
-10,000
Closed -$21.3K – 12711
2025
Q1 		$21.3K Sell
10,000
-16,400
-62% -$49.2K ﹤0.01% 13095
2024
Q4 		$84.2K Buy
26,400
+23,500
+810% +$192K ﹤0.01% 11716
2024
Q3 		$38.7K Buy
+2,900
New +$38.6K ﹤0.01% 12174

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Citadel Advisors's CATX Position: Q2 2026 in Review

Citadel Advisors increased its Perspective Therapeutics (CATX) stake by 6.7% in Q2 2026, buying an estimated $904K and bringing the position to 3,805,739 shares worth $13M. The position accounts for ﹤0.01% of the portfolio, ranked #3170.

Citadel Advisors first reported a position in CATX in Q4 2013 and has held it in 39 quarters since. The position peaked at $14.9M in Q1 2026. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Citadel Advisors held 3,805,739 shares of Perspective Therapeutics worth $13M as of Q2 2026.
  • Citadel Advisors bought 239,235 Perspective Therapeutics shares in Q2 2026, an estimated $904K.
  • Perspective Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3170 holding.
  • Citadel Advisors first reported a position in Perspective Therapeutics in Q4 2013 and has held it in 39 quarters since.
  • Citadel Advisors's Perspective Therapeutics position peaked at $14.9M in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.